• Home
  • News
  • Analysis
  •  
    Regions
    • Australasia
    • Southeast Asia
    • Greater China
    • North Asia
    • South Asia
    • North America
    • Europe
    • Central Asia
    • MENA
  •  
    Funds
    • LPs
    • Buyout
    • Growth
    • Venture
    • Renminbi
    • Secondary
    • Credit/Special Situations
    • Infrastructure
    • Real Estate
  •  
    Investments
    • Buyout
    • Growth
    • Early stage
    • PIPE
    • Credit
  •  
    Exits
    • IPO
    • Open market
    • Trade sale
    • Buyback
  •  
    Sectors
    • Consumer
    • Financials
    • Healthcare
    • Industrials
    • Infrastructure
    • Media
    • Technology
    • Real Estate
  • Events
  • Chinese edition
  • Data & Research
  • Weekly Digest
  • Newsletters
  • Sign in
  • Events
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)870 240 8859

      Email: customerservices@incisivemedia.com

      • Sign in
     
      • Saved articles
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • RSS
    • Twitter
    • LinkedIn
    • Newsletters
  • Free Trial
  • Subscribe
  • Weekly Digest
  • Chinese edition
  • Data & Research
    • Latest Data & Research
      Ape-directory
      AVCJ Private Equity Online Directory

      With its wide network of senior industry contacts, the directory is the most comprehensive online directory on private equity and venture capital in Asia. It is easy to navigate, enabling access to Asian private equity firms and professionals.

      Read more
      2016-china-cover
      Regional Reports

      The reports review the year's local private equity and venture capital activity and are filled with up-to-date data and intelligence on fundraising, investments, exits and M&A. The regional reports also feature information on key companies.

      Read more
      2016-pevc-cover
      Industry Review

      Asian Private Equity and Venture Capital Review provides an independent overview of the private equity, venture capital and M&A activities in the Asia region. It delivers insights on investments made, capital raised, sector specific figures and more.

      Read more
      AVCJ Database

      AVCJ Database is the ultimate link between Asian dealmakers and those who provide advisory, financial, legal and technological services to the private equity, venture capital and M&A industries. It is packed with facts and figures on more than 153,000 companies and almost 117,000 transactions.

      Read more
AVCJ
AVCJ
  • Home
  • News
  • Analysis
  • Regions
  • Funds
  • Investments
  • Exits
  • Sectors
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)870 240 8859

    Email: customerservices@incisivemedia.com

    • Sign in
 
    • Saved articles
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 

Healthcare

car-t-cell
China cell therapy developer raises $75m

Iaso Biotherapeutics, a Chinese cell therapy developer focusing on oncology treatments, has raised nearly CNY 500m (USD 75m) in an extended Series C round.

  • Greater China
  • 26 January 2023
healthcare-stethoscope-s
ADB backs Quadria's third health fund

Asian Development Bank (ADB) has committed USD 25m to the third fund from Singapore-based Quadria Capital, a healthcare-focused private equity firm.

  • Southeast Asia
  • 18 January 2023
leapfrog-logo
GP profile: LeapFrog Investments

LeapFrog Investments is broadly recognised as a pioneer of impact investing globally as well as an architect of the industry’s legitimising standards and controls. Asia has always been core

  • South Asia
  • 11 January 2023
bigmamaseafood-bowl
ICG invests in Korea's Big Mama Seafood

Intermediate Capital Group (ICG) has announced a second deal in three weeks from its fourth Asia fund – which closed last year on USD 1.1bn – with a commitment of undisclosed size to Korea-based Big Mama Seafood.

  • North Asia
  • 10 January 2023
india-map
Deal focus: TR leads $150m multi-asset secondary for India's Samara

TR Capital first worked with Samara Capital on a single-asset continuation fund for Sapphire Foods India – and saw the local Yum Brands franchisor go public about three months after the deal was announced. It has now reunited with Samara for what amounts...

  • Secondaries
  • 09 January 2023
pharmaceuticals-drugs-medicine
Advent acquires majority stake in India's Suven Pharma

Advent International has agreed to acquire a 50.1% stake in India-listed drug industry supplier Suven Pharmaceuticals for INR 63.1bn (USD 761.5m) with plans to acquire an additional 26%.

  • South Asia
  • 04 January 2023
dental-image-scan
MBK buys Korea dental scanning player Medit, Unison exits

MBK Partners has agreed to buy Medit, a South Korea-based manufacturer of 3D dental scanners, for a valuation of approximately KRW 2.4trn (USD 1.88bn). The transaction facilitates an exit for Unison Capital’s Korea business.

  • North Asia
  • 02 January 2023
adult-care-elderly-aged
Quadrant buys Australian healthcare equipment supplier

Quadrant Private Equity has bought a majority interest in Aidacare, an Australia-based distributor of healthcare equipment, with a view to supporting domestic and international growth.

  • Australasia
  • 31 December 2022
india-elderly-care-hands
NSSK exits Japan nursing care provider to Ricoh Leasing

Japan-based mid-market private equity firm NSSK has exited nursing care provider Welfare Suzuran to Ricoh Leasing, a Tokyo-listed leasing and finance company, for an undisclosed sum.

  • North Asia
  • 30 December 2022
doctor-anywhere
Singapore's Doctor Anywhere raises $38m, makes acquisition

Southeast Asia-focused telehealth platform Doctor Anywhere has closed a second tranche of Series C funding worth USD 38.8m and acquired Singapore-listed Asian Healthcare Specialists (AHS).

  • Southeast Asia
  • 26 December 2022
biopharma-test-tubes
KKR buys Japan's Bushu Pharmaceuticals from BPEA EQT

KKR has agreed to buy Japan-based contract drug manufacturer Bushu Pharmaceuticals from BPEA EQT – formerly Baring Private Equity Asia – for an undisclosed sum.

  • North Asia
  • 23 December 2022
healthcare-pharma-lab-drug-biotech
Co-Stone leads $43m round for China biosynthesis player

Co-Stone Capital Management has led a CNY 300m (USD 43m) Series B round for Readline, a Shenzhen-based company that specialises in synthetic biology.

  • Greater China
  • 18 December 2022
healthcare-medical-app
Australia’s Heal Partners closes debut fund on $137m

Australia’s Heal Partners, a health, education, and lifestyle-focused venture capital firm, has closed its first fund on AUD 200m (USD 137m). The target was AUD 100m.

  • Australasia
  • 18 December 2022
biopharma-test-tubes
Hillhouse buys Australia CRO George Clinical

Hillhouse Capital has agreed to buy George Clinical, an Australia-based clinical research organisation (CRO) with a global footprint, for an undisclosed sum.

  • Australasia
  • 12 December 2022
doctor-hospital-heart-surgery-operation
China medical devices manufacturer LavaMed raises $40m

SuZhou LavaMed, a China-based medical devices manufacturer, has raised USD 40m in angel and Series A funding from Zhejiang Silk Road Fund, Junshang Capital, and Lilly Asia Ventures (LAV).

  • Greater China
  • 09 December 2022
philip-liang-e15
Hong Kong’s E15 VC raises $61m for third fund

Hong Kong’s E15 VC has hit a first close of USD 60.75m on its third global deep tech fund with an anchor investment from existing cornerstone LP Sun Hung Kai & Co (SHK).

  • Greater China
  • 09 December 2022
covid-vaccine
Australian needle-free vaccine start-up raises $23m

OneVentures and UniQuest have led a AUD 34m (USD 23m) funding round for Vaxxas, an Australia-based biotechnology company running clinical programmes that include a needle-free COVID-19 vaccine candidate.

  • Australasia
  • 07 December 2022
pharma-drugs-pills
China CRO Safe Pharma gets $71m Series D

Safe Pharmaceutical Research Institute, a Beijing-based clinic research organization (CRO) focused on novel drugs, has raised a CNY500m (USD 71m) Series D round led by SDIC Venture Capital and China State-owned Venture Capital Fund.

  • Greater China
  • 06 December 2022
lifestyles
Chinese investors sell international assets of condom maker LifeStyles

A Chinese investor group featuring several private equity firms has sold the non-China assets of LifeStyles Healthcare, a global sexual health and wellness platform best known for the Lifestyles condom brand, to US-based Linden Capital Partners.

  • Greater China
  • 05 December 2022
singapore-night-street
CEO of Singapore's EDBI departs to launch own fund

Swee Yeok Chu, CEO and president of Singapore government investor EDBI, is stepping down from her role with a view to launching her own fund.

  • Southeast Asia
  • 30 November 2022
diagnostic-imaging-radiology-scan
Deal focus: IFM secures debut long-term capital deal

Targeting PRP Diagnostic Imaging through its long-hold fund meant IFM Investors could offer the company stability and partnership. It expects to generate dividend yield and capital growth

  • Australasia
  • 29 November 2022
james-huang-kpcb
Fund focus: Panacea defies biotech downturn

Having raised its second fund amid weakening investor sentiment for biotech, Panacea Venture expects deployment to be guided by a widening valuation gap between the US and China

  • Greater China
  • 29 November 2022
avcj-tejas-day03-157
Tread more cautiously in PE-infra overlap – AVCJ Forum

Investors are increasingly challenged to reconcile a vanishing divide between some infrastructure and PE strategies, the AVCJ Private Equity & Venture Forum heard.

  • Infrastructure
  • 18 November 2022
james-huang-kpcb
Panacea closes second healthcare fund on $276m

Panacea Venture, a healthcare-focused investment firm established by James Huang, formerly a partner at KPCB China, has closed its second fund with approximately USD 276m in commitments.

  • Greater China
  • 16 November 2022
1 2 3

Most read

ipo-india-money
Asia IPOs gone cold: India edition
lidar
China LiDAR specialist Hesai aims for US IPO
payment-debit
Indonesia fintech start-up iSeller gets $12m
dog-feed-woman-pet-food
Hillhouse-backed China pet services business seeks US listing
contest-battle-compete-tug-war
Australia's Potentia contests Nitro merger plan
  • About AVCJ
  • Advertise
  • Contacts
  • About ION Analytics
  • Terms of use
  • Privacy policy
  • Group disclaimer
  • RSS
  • Twitter
  • LinkedIn
  • Newsletters

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013